CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Myokardia Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Myokardia Inc
1000 Sierra Point Parkway
Phone: (650) 741-0900p:650 741-0900 Brisbane, CA  94005  United States Ticker: MYOKMYOK

This company was Merged or Acquired on 11/17/2020.
This company ceased filing statements with the SEC on 11/27/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202012/31/2019YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Mark L.Perry 64 3/1/2018 12/1/2012
President, Chief Executive Officer, Director Tassos A.Gianakakos 47 10/1/2013 10/1/2013
Chief Financial Officer Taylor C.Harris 44 4/4/2018 4/4/2018
8 additional Officers and Directors records available in full report.

Business Names
Business Name
MYOK
MyoKardia Australia Pty Ltd.
MyoKardia Netherlands B.V.

General Information
Number of Employees: 318 (As of 9/30/2020)
Outstanding Shares: 53,322,904 (As of 11/1/2020)
Shareholders: 6
Stock Exchange: NASD
Federal Tax Id: 445500552
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023